Moran LLB - BiondVax Pharmaceuticals Chief Staff
| BVXVDelisted Stock | USD 1.35 0.03 2.17% |
Insider
Moran LLB is Chief Staff of BiondVax Pharmaceuticals
| Phone | 972 8 930 2529 |
| Web | https://www.biondvax.com |
BiondVax Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3089) % which means that it has lost $0.3089 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (56.0153) %, meaning that it created substantial loss on money invested by shareholders. BiondVax Pharmaceuticals' management efficiency ratios could be used to measure how well BiondVax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.BiondVax Pharmaceuticals currently holds 21.54 M in liabilities. BiondVax Pharmaceuticals has a current ratio of 1.68, which is within standard range for the sector. Note, when we think about BiondVax Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Surrozen | 56 | |
| Daniela Santiesteban | Salarius Pharmaceuticals | N/A | |
| Steven Martin | Armata Pharmaceuticals | 63 | |
| Christopher Garcia | Surrozen | N/A | |
| Lawrence CPA | Adial Pharmaceuticals | 68 | |
| Kyle Breidenstine | PepGen | N/A | |
| Advocate Kotler | BioLineRx | 72 | |
| , MBA | Molecular Partners AG | 51 | |
| Eddie Sullivan | SAB Biotherapeutics | 58 | |
| CPA MBA | Pharvaris BV | 63 | |
| James McArthur | PepGen | 62 | |
| Anna Moore | Transcode Therapeutics | 62 | |
| Noel MBA | PepGen | 54 | |
| Ofer BSc | Mediwound | 51 | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 46 | |
| Eric Easom | AN2 Therapeutics | 56 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Elizabeth Nguyen | Surrozen | N/A | |
| LLB BSc | BioLineRx | N/A | |
| Brian Varnum | Armata Pharmaceuticals | 64 | |
| Jennifer Cormier | PepGen | N/A | |
Management Performance
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 |
BiondVax Pharmaceuticals Leadership Team
Elected by the shareholders, the BiondVax Pharmaceuticals' board of directors comprises two types of representatives: BiondVax Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BiondVax. The board's role is to monitor BiondVax Pharmaceuticals' management team and ensure that shareholders' interests are well served. BiondVax Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BiondVax Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| BSc Eng, Chief Officer | ||
| Tamar BenYedidia, Chief Scientific Officer | ||
| Dalit Fischer, Head RD | ||
| MSc MBA, CEO Director | ||
| Moran LLB, Chief Staff |
BiondVax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BiondVax Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 | |||
| Current Valuation | 21.94 M | |||
| Shares Outstanding | 3.65 M | |||
| Shares Owned By Insiders | 20.01 % | |||
| Shares Owned By Institutions | 10.69 % | |||
| Number Of Shares Shorted | 4.88 K | |||
| Price To Earning | (4.91) X | |||
| Price To Book | 7.48 X | |||
| EBITDA | (10.5 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in BiondVax Stock
If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |